U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab as First Non-Chemotherapy Combination Regimen for Patients with Waldenström’s Macroglobulinemia, a Rare Blood Cancer
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Macroglobulinemia | Pharmaceuticals | Rituxan | Waldenstrom's Macroglobulinemia